the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

By Stadler, Walter
Interventional only

Phase III
Study No PI Title
IRB17-0410 Stadler, Walter A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC) Details
IRB16-1354 Stadler, Walter A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy Details
CIRB15-1008 Stadler, Walter A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Details
Phase II
Study No PI Title
IRB17-0565 Stadler, Walter A Phase II Study of TAK-228 in patients with previously treated metastatic renal cell carcinoma Details
IRB16-0589 Stadler, Walter A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma Details
IRB16-0930 Stadler, Walter A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK- 3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427) Details
CIRB16-1405 Stadler, Walter S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma Details
Phase I
Study No PI Title
IRB16-0589 Stadler, Walter A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma Details


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .